A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee - Full Text View

Sponsor:	Alpharma Inc.
Information provided by:	Alpharma Inc.
ClinicalTrials.gov Identifier:	NCT00420992

Purpose

The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.

Condition	Intervention	Phase
Osteoarthritis Chronic Pain	Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER) Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee

Resource links provided by NLM:

MedlinePlus related topics: Osteoarthritis

Drug Information available for: Naltrexone Naltrexone hydrochloride

U.S. FDA Resources

Further study details as provided by Alpharma Inc.:

Primary Outcome Measures:

Mean Change in Diary Brief Pain Inventory Score of Average Pain (Daily Scores of Average Pain Averaged Over 7 Days) [ Time Frame: randomization to 12 weeks following randomization ] [ Designated as safety issue: No ]

Enrollment:	547
Study Start Date:	December 2006
Study Completion Date:	November 2007
Primary Completion Date:	November 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
ALO-01: Experimental	Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER) capsules, 20-160 mg total daily dose, given either once daily or twice daily
Placebo: Placebo Comparator	Drug: Placebo capsules

Detailed Description:

The primary objective of this study is to evaluate the efficacy of ALO-01 compared with placebo for the treatment of chronic moderate to severe pain (focusing on osteoarthritis of the hip or knee) as measured by mean change in diary BPI score of average pain (daily scores of average pain averaged over 7 days) from randomization to 12 weeks following randomization.

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subject is 21 years of age or older
Subject is either not of childbearing potential OR subject must use an acceptable method of birth control if of childbearing potential
Negative pregnancy test if female of childbearing potential
Subject is in general good health
Subject required treatment of joint pain within the last 90 days
Subject has primary diagnosis of OA of the hip or knee

Exclusion Criteria:

Subject has a documented history of allergic reaction or intolerance to morphine or other opioids
Subject is pregnant or breast-feeding
Subject is receiving systemic chemotherapy
Subject has a history of drug abuse/dependence/misuse or alcohol abuse/dependence
Subject has history of major depressive disorder not controlled with medication
Subject has any chronic pain syndrome (i.e., fibromyalgia) that may interfere with the symptoms of OA
Subject has active gastrointestinal disease, with the exception of GERD
Subject has a documented history of rheumatoid arthritis, uncontrolled inflammatory arthritis or NSAID-dependent inflammatory arthritis

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00420992

Show 81 Study Locations

Sponsors and Collaborators

Alpharma Inc.

Investigators

Study Director:

James B. Jones, MD, PharmD

Alpharma Pharmceuticals

More Information

No publications provided

Responsible Party:	King Pharmaceuticals Research and Development ( Kenneth Sommerville, M.D., FAAN, Vice President, Clinical Development )
Study ID Numbers:	ALO-KNT-301
Study First Received:	January 10, 2007
Results First Received:	September 11, 2009
Last Updated:	October 28, 2009
ClinicalTrials.gov Identifier:	NCT00420992 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alpharma Inc.:

hip
knee
pain
osteoarthritis
OA
Kadian

Alpharma
naltrexone
Opioid
morphine
Embeda
ALO-01

Additional relevant MeSH terms:

Morphine
Osteoarthritis
Joint Diseases
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Osteoarthritis, Hip
Rheumatic Diseases
Pharmacologic Actions

Musculoskeletal Diseases
Sensory System Agents
Therapeutic Uses
Arthritis
Naltrexone
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on November 25, 2009